Kura Oncology (NASDAQ:KURA) Stock Rating Reaffirmed by Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a report released on Friday, Benzinga reports.

A number of other analysts also recently commented on the company. Wedbush restated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Friday. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Monday, June 24th. Stifel Nicolaus lowered their price target on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a report on Friday. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, June 18th. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $30.57.

Kura Oncology Price Performance

Shares of NASDAQ:KURA traded down $0.15 during trading on Friday, hitting $18.97. 1,107,395 shares of the stock were exchanged, compared to its average volume of 1,047,496. The company has a fifty day moving average price of $20.74 and a two-hundred day moving average price of $20.69. The company has a market cap of $1.45 billion, a PE ratio of -8.74 and a beta of 0.88. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the previous year, the business posted ($0.53) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts forecast that Kura Oncology will post -2.56 EPS for the current year.

Insider Transactions at Kura Oncology

In other news, insider Teresa Brophy Bair sold 2,615 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the completion of the transaction, the insider now directly owns 68,979 shares in the company, valued at $1,527,884.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Signaturefd LLC raised its holdings in Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after purchasing an additional 1,449 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Kura Oncology in the first quarter valued at $110,000. Saxon Interests Inc. bought a new position in shares of Kura Oncology in the first quarter valued at $201,000. Entropy Technologies LP bought a new position in shares of Kura Oncology in the first quarter valued at $218,000. Finally, Cape Investment Advisory Inc. bought a new position in shares of Kura Oncology in the fourth quarter valued at $176,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.